Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
US stocks unusual | Sanofi rose more than 1.2%, and the French government investment company is reportedly considering bidding for its health protection business.
On July 5th, Glon Hui | Sanofi (SNY.US) rose by more than 1.2%, to $49.45. On the news front, French state-owned investment company Bpifrance is considering joining the ranks of bidders for Sanofi's consumer health product business. Sanofi is negotiating the divestiture of its consumer health product branch, and options being considered include overall sale. Private equity funds such as Bain Capital and Cinven have expressed interest in purchasing related assets, and the acquisition fund PAI Partners also intends to participate in the bidding. The market estimates that the transaction value involved in the sale operation may reach as high as $20 billion.
Sector Update: Health Care Stocks Steady Premarket Friday
Health care stocks were steady premarket Friday, with the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) inactive. Bain Capital and Cinven are considering a potential jo
Sector Update: Health Care
Health care stocks were mixed premarket Friday, with the Health Care Select Sector SPDR Fund (XLV) marginally lower and the iShares Biotechnology ETF (IBB) up 0.3%. Bain Capital and Cinven are conside
Sanofi's Consumer Health Unit Receives Interest From French State
French state-owned investment firm Bpifrance is considering a stake acquisition in Sanofi's (SAN.PA) consumer health unit, Bloomberg News reported on Thursday, citing Bpifrance Executive Director Jose
French government investment company plans to compete for the acquisition of Sanofi healthcare business with a transaction value of up to 20 billion US dollars.
On July 5th, French state-owned investment company Bpifrance is considering joining the bidding for Sanofi's consumer health business. Sanofi is in talks to divest its consumer health branch, considering options including overall sales. Private equity funds such as Bain Capital and Cinven have expressed interest in acquiring related assets, and acquisition fund PAI Partners also intends to participate in the bidding. It is estimated that the transaction value involved in the sales action may be as high as $20 billion. Bpifrance Executive Director Jose Gonzalo told reporters on Thursday.
French State Investment Firm Eyes Stake in Sanofi Consumer Unit
Bain, Cinven Explore Joint Bid for Sanofi's Consumer Unit, Bloomberg Reports
--Private-equity groups Bain Capital and Cinven are weighing a potential joint offer for Sanofi's consumer-healthcare unit, while Advent International is in talks with potential partners for its own b
Dupixent, developed by Regeneron (REGN.US) and Sanofi (SNY.US), has been approved in the EU for the treatment of adult patients with chronic obstructive pulmonary disease.
Dupixent is the first new therapy approved for the treatment of COPD in the European Union for over a decade.
Kamada Draws Buy at Stifel on Underappreciated Potential
Sanofi CEO Says Talking To Private Equity For Sale Of Consumer Arm
Sanofi CEO Says Talking To Private Equity For Sale Of Consumer Arm
Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division, Bloomberg Reports
Sanofi (SNY) Price: 48.79, Change: +0.24, Percent Change: +0.50
GSK Will Pay Up to $1.5 Billion for CureVac's MRNA Vaccines -- Barrons.com
By Josh Nathan-Kazis The drugmaker GSK plunged into the messenger RNA-based vaccine market Wednesday, announcing it will buy the rights to experimental influenza and Covid-19 mRNA vaccines from the b
Argus Research Maintains Sanofi(SNY.US) With Buy Rating, Cuts Target Price to $55
Argus Research analyst Jasper Hellweg maintains $Sanofi(SNY.US)$ with a buy rating, and adjusts the target price from $60 to $55.According to TipRanks data, the analyst has a success rate of 58.9% and
Sanofi's Dupixent has been approved for the treatment of chronic obstructive pulmonary disease in the European Union.
On July 3, GLH, Sanofi announced that the EU regulatory agency approved its drug Dupixent for adults with chronic obstructive pulmonary disease in Europe. This decision makes Dupixent the first targeted therapy for about 220,000 adult patients with chronic obstructive pulmonary disease in the EU. Sanofi said the US Food and Drug Administration is also reviewing the drug and may make a decision by September 27; China's regulatory agency is also considering the drug.
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
On Wednesday, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characteriz
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
J.P. Morgan Sticks to Its Hold Rating for Sanofi (SNYNF)
Express News | The first domestic drug for infant RSV infection is officially commercially available.
Update: Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
(Updates with statement from GSK in fourth and fifth paragraphs.) A Delaware Superior Court judge rejected an appeal from GSK (GSK) and other drugmakers to overturn a ruling that cleared the way for o